AI-Assisted Post-Market Surveillance and Signal Detection: What Regulators Will Still Expect Humans to Defend
AI tools can detect signals — but regulators still expect humans to interpret, escalate, and defend every post-market surveillance decision under FDA and EU MDR.
Instructor
Meredith Crabtree
GMP Quality Consultant & Validation Specialist
What You'll Learn
About the event
About this event
Post-market surveillance programs are increasingly incorporating AI-assisted tools to support complaint analysis, signal detection, trend identification, adverse event review, and large-scale data evaluation. While these technologies may help organizations process growing volumes of information more efficiently, regulatory responsibility for safety decisions, escalation activities, risk assessments, MDR reporting, and post-market actions continues to remain firmly with the organization. Questions are increasingly emerging around how AI-supported outputs are interpreted, challenged, verified, and ultimately defended when product safety concerns arise within FDA, EU MDR, and other regulated post-market environments.
This session examines the practical realities of using AI-assisted approaches within post-market surveillance activities while maintaining defensible regulatory oversight. The discussion will focus on signal evaluation, complaint review processes, documentation practices, escalation decisions, and the role of human judgment when automated tools contribute to safety-related assessments. Participants will better understand where organizations remain accountable, how oversight expectations may be applied in practice, and what regulators will still expect teams to explain, justify, and defend.
WHY YOU SHOULD ATTEND
Finding potential signals is rarely the difficult part of post-market surveillance. Organizations routinely collect complaint information, adverse event data, MDR submissions, service records, and other sources of post-market evidence. The difficult decisions begin when teams must determine whether a pattern is meaningful, whether additional investigation is justified, whether escalation is warranted, or whether available evidence supports reporting, field action, or continued monitoring. As AI-assisted tools become more capable of identifying patterns and anomalies, the volume of information requiring interpretation may increase significantly while responsibility for the resulting decisions remains unchanged.
FDA and EU MDR requirements do not evaluate whether an algorithm identified a signal. They evaluate how the organization interpreted the information, what actions were taken, what evidence supported those actions, and how conclusions were ultimately reached. This session focuses on the judgment, rationale, and decision-making processes that remain essential within post-market surveillance programs regardless of how sophisticated the underlying technology becomes.
Code: FDB1417
Curriculum
Requirements
- Working in FDA or EU MDR regulated medical device or life sciences industries
- Familiarity with post-market surveillance, complaint handling, or vigilance programs
- Applicable to quality, regulatory affairs, product safety, and compliance professionals
Who Should Attend
This session is designed for professionals responsible for post-market surveillance, complaint handling, adverse event reporting, and product safety in FDA and EU MDR regulated environments. A must-attend for: Quality Assurance (QA) Departments, Regulatory Affairs Departments, Manufacturing Departments, Operations Departments, Compliance Departments, Post-Market Surveillance Teams, Complaint Handling and Vigilance Personnel, Product Safety and Risk Management Teams.
Areas Covered
Meet Your Instructor
Meredith Crabtree
GMP Quality Consultant & Validation Specialist
Meredith Crabtree has over 30 years' experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations. Meredith is the owner of MLKC Consulting and specializes in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.
Event Details
Format
Recorded Webinar
Duration
1.5 hours
Certificate
Included
Access
Lifetime
Related Events
Digital Quality Metrics and AI/ML Analytics: Building a Continuous-Improvement Framework that Aligns with Regulatory Expectations
Learn how AI/ML and real-time digital quality metrics build a continuous-improvement framework aligned with FDA regulatory expectations, 21 CFR Part 11, and GAMP®5.
Carolyn Troiano
AI in GMP: What the FDA Is Already Expecting - Before You Ask
FDA already expects GMP compliance for AI systems. Learn how existing validation, data integrity, and oversight rules apply—before regulators come calling.
Dr. Ginette Collazo
HPLC Analytical Method Development and Validation
Master HPLC instrument and method validation to meet US EPA and FDA requirements for pharmaceutical analysis.
Dr. John C. Fetzer